Rhythm Pharmaceuticals (BMV:RYTM *) - Aktienkurs, Nachrichten und Analyse

RYTM * Aktienübersicht

Rhythm Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die seltenen neuroendokrinen Erkrankungen konzentriert.

Über das Unternehmen

RYTM * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Belohnungen

77.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 65.62% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Die Aktionäre wurden im vergangenen Jahr verwässert

Rhythm Pharmaceuticals, Inc. Wettbewerber

Sinocelltech Group

SHSE:688520

CN¥19.4b

Telix Pharmaceuticals

ASX:TLX

AU$6.0b

Beam Therapeutics

NasdaqGS:BEAM

US$2.0b

Ardelyx

NasdaqGM:ARDX

US$1.5b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Rhythm Pharmaceuticals
Historical stock prices
Current Share Price	US$680.21
52 Week High	US$733.48
52 Week Low	US$427.50
Beta	1.93
1 Month Change	0%
3 Month Change	5.15%
1 Year Change	120.85%
3 Year Change	53.82%
5 Year Change	59.00%
Change since IPO	59.00%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	RYTM *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	120.8%	0%	0%

Rendite im Vergleich zur Industrie: RYTM * übertraf die Branche MX Biotechs , die im vergangenen Jahr eine Rendite von 1.5 erzielte.

Rendite vs. Markt: RYTM * übertraf den Markt MX, der im vergangenen Jahr eine Rendite von -4.3 erzielte.

Preisvolatilität

Is RYTM *'s price volatile compared to industry and market?
RYTM * volatility
RYTM * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: RYTM * hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: [Unzureichende Daten]], um die Volatilitätsveränderung von RYTM * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2008	226	David Meeker	rhythmtx.com

Rhythm Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich auf seltene neuroendokrine Erkrankungen konzentriert. Der führende Produktkandidat des Unternehmens ist IMCIVREE (Setmelanotid), ein seltener Melanocortin-4-Rezeptor für die Behandlung von Adipositas mit Pro-Opiomelanocortin (POMC), Proprotein-Convertase-Subtilisin/Kexin-Typ 1 und Leptin-Rezeptor (LEPR) Mangel sowie Bardet-Biedl- und Alström-Syndrom. Es befindet sich in klinischen Phase-3-Studien zur Behandlung von Fettleibigkeit bei heterozygotem POMC- oder LEPR-Mangel, Fettleibigkeit bei Steroidrezeptor-Coaktivator-1-Mangel, Fettleibigkeit bei SH2B1-Mangel, Fettleibigkeit bei MC4-Rezeptor-Mangel und anderen MC4R-Erkrankungen.

Rhythm Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Rhythm Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
RYTM * grundlegende Statistiken
Marktanteil	Mex$46.55b
Gewinn(TTM)	-Mex$5.08b
Umsatz(TTM)	Mex$1.71b

27.3x

Kurs-Umsatz-Verhältnis

-9.2x

Kurs-Gewinn-Verhältnis

Ist RYTM * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RYTM * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$91.93m
Kosten der Einnahmen	US$10.69m
Bruttogewinn	US$81.24m
Sonstige Ausgaben	US$355.11m
Umsatz	-US$273.87m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-4.49
Bruttomarge	88.37%
Nettogewinnspanne	-297.93%
Schulden/Eigenkapital-Verhältnis	174.4%

Wie hat sich RYTM * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

RYTM * Aktienübersicht

Belohnungen

Risikoanalyse

Rhythm Pharmaceuticals, Inc. Wettbewerber

SHSE:688520

CN¥19.4b

ASX:TLX

AU$6.0b

NasdaqGS:BEAM

US$2.0b

NasdaqGM:ARDX

US$1.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Recent updates

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2026

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Rhythm Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

27.3x

-9.2x

Erträge &amp; Einnahmen

Erträge & Einnahmen